Dr. Martien Borgdorff has recently been appointed Executive Director of the KNCV Tuberculosis Foundation, a founding TB Alliance Stakeholder and leading European TB control organization. He assumes the position from Dr. Jaap Broekmans, who is shifting to an advisory role after 17 years of leading the Foundation.
"We warmly congratulate Dr. Borgdorff on his appointment. His expertise has been invaluable in our modeling project and we look forward to continuing to work closely with him in his new capacity," said Dr. Maria C. Freire, President and CEO of the TB Alliance.
A public health expert with more than 30 years of experience, Dr. Borgdorff has been with the KNCV Tuberculosis Foundation since 1996, and is also currently Professor of International Health at the University of Amsterdam. Dr. Borgdorff has also played a key advisory role in an epidemiological study commissioned by the TB Alliance to examine the impact of a shorter two-month TB drug regimen for the Millennium Project Task Force on TB.
Dr. Borgdorff has authored more than 100 peer-reviewed articles, and holds a Ph.D. in Epidemiology from the University of Amsterdam, a M.Sc. in Community Health in Developing Countries from the London School of Hygiene and Tropical Medicine, and a M.D. from the University of Utrecht. He serves as a member of the Stop TB Partnership Strategic and Technical Advisory Group, and is associate editor of the International Journal on Tuberculosis and Lung Disease.
Based in The Hague, the KNCV Tuberculosis Foundation is a leading medical development organization that seeks to promote effective and efficient TB control at both the national and international levels.